文献速递重症综合管理与镇静镇痛创伤与烧伤

脑死亡前激素替代治疗提高灾难性脑损伤后器官捐献率:EAST多中心试验

Hormone replacement before brain death increases organ donation rate after catastrophic brain injury: An EAST multicenter trial.
PubMed 文献 · J Trauma Acute Care Surg · 2026-07-17
一句话结论成人灾难性脑损伤患者脑死亡前接受激素替代治疗与器官捐献几率显著增加相关,甲泼尼龙联合左甲状腺素组合的捐献几率增幅最大。

这项前瞻性观察性EAST多中心试验纳入2022年1月至2025年6月38家Ⅰ级和Ⅱ级创伤中心的1184例成人灾难性脑损伤患者,其中704例接受至少一种激素治疗。269例成为器官捐献者,227例接受了激素替代治疗。广义线性混合模型校正人口学和临床差异后发现,单用类固醇、左甲状腺素、血管加压素、多巴胺、DDAVP或胰岛素均与器官捐献几率增加相关,甲泼尼龙联合左甲状腺素的组合捐献几率增幅最大。结论认为脑死亡前给予激素替代治疗与器官捐献显著增加相关,建议创伤中心采用标准化方案。

要点

  • 1184例成人灾难性脑损伤患者中704例接受至少一种激素,269例成为器官捐献者,其中227例接受激素替代治疗。
  • 广义线性混合模型校正人口学和临床差异后,单用类固醇、左甲状腺素、血管加压素、多巴胺、DDAVP或胰岛素均与器官捐献几率增加相关。
  • 甲泼尼龙联合左甲状腺素的组合与器官捐献几率增幅最大相关。
  • 激素替代治疗患者在脑死亡前给药,与器官捐献显著增加相关。
  • 研究为前瞻性观察性设计,证据等级Level II,结论为相关性而非因果性。

适用人群与场景

  • 38家Ⅰ级和Ⅱ级创伤中心的成人灾难性脑损伤患者,灾难性脑损伤定义为导致脑干以上功能丧失并随后死亡的脑损伤。

诊断标准与关键阈值

  • 灾难性脑损伤定义:导致脑干以上功能丧失并随后死亡的脑损伤。

处置流程与药物剂量

  • 原文未提及具体给药剂量、途径、频次或目标值。
  • 原文提及的激素包括类固醇、左甲状腺素、血管加压素、多巴胺、DDAVP、胰岛素,以及甲泼尼龙联合左甲状腺素组合。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:前瞻性观察性EAST多中心试验,38家Ⅰ级和Ⅱ级创伤中心,2022年1月至2025年6月。
  • 样本量:1184例成人灾难性脑损伤患者,704例接受至少一种激素,269例器官捐献者中227例接受激素替代治疗。
  • 激素替代治疗患者更年轻、男性更多、穿透性脑损伤比例更高、已知合并症比例更低,ISS更高,但组间 abbreviated injury scale-head 评分无差异。
  • 广义线性混合模型校正人口学和临床差异后,单用类固醇、左甲状腺素、血管加压素、多巴胺、DDAVP或胰岛素均与器官捐献几率增加相关。
  • 甲泼尼龙联合左甲状腺素的组合与器官捐献几率增幅最大相关。

证据类型、等级与局限

  • 证据类型:前瞻性观察性多中心试验。
  • 证据等级:Level II(预后与流行病学)。
  • 局限:观察性设计,激素替代治疗组与非激素替代治疗组存在基线差异(年龄、性别、损伤类型、合并症、ISS),虽经广义线性混合模型校正,仍不能排除残余混杂,结论为相关性而非因果性。

对床旁实践的改变

  • 对成人灾难性脑损伤患者在脑死亡前考虑使用激素替代治疗可能增加器官捐献几率,但需注意本研究为观察性设计,不能确立因果。
  • 甲泼尼龙联合左甲状腺素组合与器官捐献几率增幅最大相关,但原文未提供具体剂量方案。
  • 原文建议创伤中心采用包含激素替代治疗的标准化方案以最大化不可挽救性颅脑创伤患者的器官捐献。

指南或共识出处

  • J Trauma Acute Care Surg. 2026;101:619-631.

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: One third of organ donors die due to catastrophic brain injury (CBI). CBI causes massive physiological derangements that can damage organs and prevent organ donation. Hormone replacement therapy (HRT) can mitigate this damage when given in the critical care setting, but no standardized protocol for use at trauma centers exists. Single-center studies show that HRT increases organ donation, but there has not been an investigation on which hormone combinations are most beneficial.

METHODS: This prospective, observational EAST multicenter trial included adult CBI patients at 38 Level I and II trauma centers from January 2022 to June 2025. CBI was defined as a brain injury causing loss of function above the brain stem and subsequent death. A generalized linear mixed model analyzed the association of HRT and organ donation.

RESULTS: Of 1,184 CBI patients, 704 received at least one hormone. There were 269 organ donors, and 227 received HRT. HRT patients were younger, more often male, sustained higher rates of penetrating brain injuries, and had lower rates of known comorbidities compared with non-HRT patients. HRT patients had higher ISS, but there was no difference in abbreviated injury scale-head scores between groups. GLMM analysis accounted for demographic and clinical differences between groups and found that single-hormone replacement with steroids, levothyroxine, vasopressin, dopamine, DDAVP, or insulin was associated with increased odds ratios of organ donation compared with no HRT. The combination of methylprednisolone and levothyroxine was associated with the greatest increased odds of donation.

CONCLUSIONS: When administered to CBI patients before brain death, HRT is associated with significantly increased odds of organ donation. A standardized protocol incorporating HRT should be utilized across trauma centers to maximize organ donation in patients who have suffered nonsurvivable head trauma. ( J Trauma Acute Care Surg . 2026;101: 619-631.).

LEVEL OF EVIDENCE: Prognostic and Epidemiological; Level II.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Nordham KD, Tatum D, Patel MB, et al. Hormone replacement before brain death increases organ donation rate after catastrophic brain injury: An EAST multicenter trial. J Trauma Acute Care Surg. 2026. PMID: 42468021. doi:10.1097/TA.0000000000005029

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。